Glucose metabolism continuous deteriorating in male patients with human immunodeficiency virus accepted antiretroviral therapy for 156 weeks

Figure 2 Long-term dynamic changes in fasting plasma glucose, glycosylated hemoglobin A1c and impaired fasting plasma glucose within 156 wk after the initiation of antiretroviral therapy with tenofovir plus lamivudine plus efavirenz in male patients living with human immunodeficiency virus (including normal glucose tolerance and prediabetes) (n = 61). A: Fasting plasma glucose (FPG) level; B: Glycosylated hemoglobin A1c (HbA1c) level; C: Impaired fasting plasma glucose rate. ANOVA was used to compare FPG and HbA1c from baseline to 156 wk (A, B, all P<0.0001). A paired t test was used to compare FPG and HbA1c between baseline and specific follow-up time points, ^aP < 0.05, ^bP < 0.01. The chi-square test was used to compare the percentage of IFG from baseline to 156 wk (C, P < 0.0001) and between baseline and specific follow-up time points, ^bP < 0.01.